NewEdge Advisors’s Immunocore IMCR Stock Holding History

NewEdge Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-90	Closed	-$5.85K	–	3896
2024 Q1	$5.85K	Sell	90 -40	-31%	-$2.75K	﹤0.01%	3082
2023 Q4	$8.88K	Buy	+130	New	+$6.76K	﹤0.01%	2910

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NewEdge Advisors's IMCR Position: Q2 2024 in Review

NewEdge Advisors sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 90 shares — an estimated $5.85K sold.

NewEdge Advisors first reported a position in IMCR in Q4 2023 and held it in 2 quarters. The position peaked at $8.88K in Q4 2023. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

NewEdge Advisors reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
NewEdge Advisors sold 90 Immunocore shares in Q2 2024, an estimated $5.85K.
NewEdge Advisors first reported a position in Immunocore in Q4 2023 and held it in 2 quarters.
NewEdge Advisors's Immunocore position peaked at $8.88K in Q4 2023.
138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on NewEdge Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.